BioCatalystWatch
IRDWorkspace / IRD / OverviewCompany library
Price
Market cap
Next catalystExpected Q4 2026OPGx-RDH12 — planned Phase 1/2 dosing · Trial initiationCompany release ↗
Cash

Chart & Events

Candle interval

Core Clinical

Phentolamine Ophthalmic Solution 0.75% (RYZUMVI)

α1-adrenergic receptor × α2-adrenergic receptor

PreINDP1P2P3FilingApproved
OPGx-BEST1

Functional BEST1 gene × VMD2/BEST1 promoter

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

OPGx-RDH12

RDH12 × Functional RDH12 gene × Functional RDH12 enzyme

PreINDP1P3FilingApproved
Upcoming / outlook

OPGx-LCA5

Functional LCA5 gene

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

OPGx-BEST1

Functional BEST1 gene × VMD2/BEST1 promoter

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

OPGx-RDH12

RDH12 × Functional RDH12 gene × Functional RDH12 enzyme

PreINDP1P3FilingApproved
Upcoming / outlook

OPGx-LCA5

Functional LCA5 gene

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Phentolamine Ophthalmic Solution 0.75% (RYZUMVI)

α1-adrenergic receptor × α2-adrenergic receptor

PreINDP1P2P3FilingApproved

Other pipelines

OPGx-LCA5

Functional LCA5 gene

PreINDP1P2P3FilingApproved

OPGx-RHO

RHO (rhodopsin) × shRNA820 × RHO820

OPGx-002

RDH12 gene

PreINDP1P2P3FilingApproved
OPGx-003

PreINDP1P2P3FilingApproved
OPGx-NMNAT1

PreINDP1P2P3FilingApproved

Partner / License out

APE1/Ref-1

APE1/Ref-1

Approved / commercial

α1-adrenergic receptor × α2-adrenergic receptor

PreINDP1P2P3FilingApproved
Phentolamine Ophthalmic Solution 0.75% (RYZUMVI)

α1-adrenergic receptor × α2-adrenergic receptor

Approved

PreINDP1P2P3FilingApproved

History / paused

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Company funding outlook

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

IRD PR & News

IRD SEC archive